Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 28

1.

Durable Clinical Benefit in Patients with Advanced Cutaneous Melanoma after Discontinuation of Anti-PD-1 Therapies Due to Immune-Related Adverse Events.

Swami U, Monga V, Bossler AD, Zakharia Y, Milhem M.

J Oncol. 2019 Jul 25;2019:1856594. doi: 10.1155/2019/1856594. eCollection 2019.

2.

Urothelial carcinoma with an NRF1-BRAF rearrangement and response to targeted therapy.

Isaacson AL, Guseva NV, Bossler AD, Ma D.

Cold Spring Harb Mol Case Stud. 2019 Jun 3;5(3). pii: a003848. doi: 10.1101/mcs.a003848. Print 2019 Jun.

3.

BCR-NTRK2 fusion in a low-grade glioma with distinctive morphology and unexpected aggressive behavior.

Jones KA, Bossler AD, Bellizzi AM, Snow AN.

Cold Spring Harb Mol Case Stud. 2019 Apr 1;5(2). pii: a003855. doi: 10.1101/mcs.a003855. Print 2019 Apr.

4.

Exceptional responses with sequential metronomic temozolomide after pembrolizumab failure in patients with metastatic melanoma.

Swami U, Monga V, Freesmeier M, Zhang W, Bossler AD, Zakharia Y, Milhem M.

Melanoma Res. 2019 Dec;29(6):643-647. doi: 10.1097/CMR.0000000000000592.

PMID:
30829928
5.

Toxicities with targeted therapies after immunotherapy in metastatic melanoma.

Grogan N, Swami U, Bossler AD, Zakharia Y, Milhem M.

Melanoma Res. 2018 Dec;28(6):600-604. doi: 10.1097/CMR.0000000000000493.

6.

TRAPPC11 and GOSR2 mutations associate with hypoglycosylation of α-dystroglycan and muscular dystrophy.

Larson AA, Baker PR 2nd, Milev MP, Press CA, Sokol RJ, Cox MO, Lekostaj JK, Stence AA, Bossler AD, Mueller JM, Prematilake K, Tadjo TF, Williams CA, Sacher M, Moore SA.

Skelet Muscle. 2018 May 31;8(1):17. doi: 10.1186/s13395-018-0163-0.

7.

Biallelic TP53 gain of function mutations in rapidly progressing solid tumors.

Sande CM, Chang B, Monga V, Bossler AD, Ma D.

Cancer Genet. 2018 Apr;222-223:20-24. doi: 10.1016/j.cancergen.2018.02.001. Epub 2018 Feb 24.

PMID:
29666004
8.

Correction to: Genomics of NSCLC patients both affirm PD-L1 expression and predict their clinical responses to anti-PD-1 immunotherapy.

Brogden KA, Parashar D, Hallier AR, Braun T, Qian F, Rizvi NA, Bossler AD, Milhem MM, Chan TA, Abbasi T, Vali S.

BMC Cancer. 2018 Apr 12;18(1):413. doi: 10.1186/s12885-018-4200-5.

9.

Genomics of NSCLC patients both affirm PD-L1 expression and predict their clinical responses to anti-PD-1 immunotherapy.

Brogden KA, Parashar D, Hallier AR, Braun T, Qian F, Rizvi NA, Bossler AD, Milhem MM, Chan TA, Abbasi T, Vali S.

BMC Cancer. 2018 Feb 27;18(1):225. doi: 10.1186/s12885-018-4134-y. Erratum in: BMC Cancer. 2018 Apr 12;18(1):413.

10.

Simultaneous detection of single-nucleotide variant, deletion/insertion, and fusion in lung and thyroid carcinoma using cytology specimen and an RNA-based next-generation sequencing assay.

Guseva NV, Jaber O, Stence AA, Sompallae K, Bashir A, Sompallae R, Bossler AD, Jensen CS, Ma D.

Cancer Cytopathol. 2018 Mar;126(3):158-169. doi: 10.1002/cncy.21963. Epub 2018 Jan 24.

11.

Targeting epigenetics for treatment of BRAF mutated metastatic melanoma with decitabine in combination with vemurafenib: A phase lb study.

Zakharia Y, Monga V, Swami U, Bossler AD, Freesmeier M, Frees M, Khan M, Frydenlund N, Srikantha R, Vanneste M, Henry M, Milhem M.

Oncotarget. 2017 Sep 26;8(51):89182-89193. doi: 10.18632/oncotarget.21269. eCollection 2017 Oct 24.

12.

Anchored multiplex PCR for targeted next-generation sequencing reveals recurrent and novel USP6 fusions and upregulation of USP6 expression in aneurysmal bone cyst.

Guseva NV, Jaber O, Tanas MR, Stence AA, Sompallae R, Schade J, Fillman AN, Miller BJ, Bossler AD, Ma D.

Genes Chromosomes Cancer. 2017 Apr;56(4):266-277. doi: 10.1002/gcc.22432. Epub 2016 Dec 2.

PMID:
27910166
13.

The NAB2-STAT6 gene fusion in solitary fibrous tumor can be reliably detected by anchored multiplexed PCR for targeted next-generation sequencing.

Guseva NV, Tanas MR, Stence AA, Sompallae R, Schade JC, Bossler AD, Bellizzi AM, Ma D.

Cancer Genet. 2016 Jul-Aug;209(7-8):303-12. doi: 10.1016/j.cancergen.2016.05.071. Epub 2016 May 24.

PMID:
27292373
14.

Genomic Sequencing Procedure Microcosting Analysis and Health Economic Cost-Impact Analysis: A Report of the Association for Molecular Pathology.

Sabatini LM, Mathews C, Ptak D, Doshi S, Tynan K, Hegde MR, Burke TL, Bossler AD.

J Mol Diagn. 2016 May;18(3):319-328. doi: 10.1016/j.jmoldx.2015.11.010. Epub 2016 Apr 13. Review.

15.

Germline mutations predisposing to non-small cell lung cancer.

Clamon GH, Bossler AD, Abu Hejleh T, Furqan M.

Fam Cancer. 2015 Sep;14(3):463-9. doi: 10.1007/s10689-015-9796-x. Review.

PMID:
25813228
16.

A simple and cost-effective method of DNA extraction from small formalin-fixed paraffin-embedded tissue for molecular oncologic testing.

Snow AN, Stence AA, Pruessner JA, Bossler AD, Ma D.

BMC Clin Pathol. 2014 Jul 7;14:30. doi: 10.1186/1472-6890-14-30. eCollection 2014.

17.

Evaluation of the Bruker Biotyper and Vitek MS matrix-assisted laser desorption ionization-time of flight mass spectrometry systems for identification of nonfermenting gram-negative bacilli isolated from cultures from cystic fibrosis patients.

Marko DC, Saffert RT, Cunningham SA, Hyman J, Walsh J, Arbefeville S, Howard W, Pruessner J, Safwat N, Cockerill FR, Bossler AD, Patel R, Richter SS.

J Clin Microbiol. 2012 Jun;50(6):2034-9. doi: 10.1128/JCM.00330-12. Epub 2012 Apr 11.

18.

FSH dystrophy and a subtelomeric 4q haplotype: a new assay and associations with disease.

Tsumagari K, Chen D, Hackman JR, Bossler AD, Ehrlich M.

J Med Genet. 2010 Nov;47(11):745-51. doi: 10.1136/jmg.2009.076703. Epub 2010 Aug 15.

19.

Muscle-Eye-Brain disease.

Shenoy AM, Markowitz JA, Bonnemann CG, Krishnamoorthy K, Bossler AD, Tseng BS.

J Clin Neuromuscul Dis. 2010 Mar;11(3):124-6. doi: 10.1097/CND.0b013e3181c5054d.

20.

Human papillomavirus (HPV) type 18 induces extended growth in primary human cervical, tonsillar, or foreskin keratinocytes more effectively than other high-risk mucosal HPVs.

Lace MJ, Anson JR, Klingelhutz AJ, Lee JH, Bossler AD, Haugen TH, Turek LP.

J Virol. 2009 Nov;83(22):11784-94. doi: 10.1128/JVI.01370-09. Epub 2009 Sep 9.

21.

Impaired PTPN13 phosphatase activity in spontaneous or HPV-induced squamous cell carcinomas potentiates oncogene signaling through the MAP kinase pathway.

Hoover AC, Strand GL, Nowicki PN, Anderson ME, Vermeer PD, Klingelhutz AJ, Bossler AD, Pottala JV, Hendriks WJ, Lee JH.

Oncogene. 2009 Nov 12;28(45):3960-70. doi: 10.1038/onc.2009.251. Epub 2009 Sep 7.

22.

Interferon-beta treatment increases human papillomavirus early gene transcription and viral plasmid genome replication by activating interferon regulatory factor (IRF)-1.

Lace MJ, Anson JR, Klingelhutz AJ, Harada H, Taniguchi T, Bossler AD, Haugen TH, Turek LP.

Carcinogenesis. 2009 Aug;30(8):1336-44. doi: 10.1093/carcin/bgp150. Epub 2009 Jun 18.

PMID:
19541854
23.

The PDZ binding motif of human papillomavirus type 16 E6 induces PTPN13 loss, which allows anchorage-independent growth and synergizes with ras for invasive growth.

Spanos WC, Hoover A, Harris GF, Wu S, Strand GL, Anderson ME, Klingelhutz AJ, Hendriks W, Bossler AD, Lee JH.

J Virol. 2008 Mar;82(5):2493-500. Epub 2007 Dec 26.

24.

Deletion of the PDZ motif of HPV16 E6 preventing immortalization and anchorage-independent growth in human tonsil epithelial cells.

Spanos WC, Geiger J, Anderson ME, Harris GF, Bossler AD, Smith RB, Klingelhutz AJ, Lee JH.

Head Neck. 2008 Feb;30(2):139-47.

25.

A novel t(3;8)(q27;q24.1) simultaneously involving both the BCL6 and MYC genes in a diffuse large B-cell lymphoma.

Wang HY, Bossler AD, Schaffer A, Tomczak E, DiPatri D, Frank DM, Nowell PC, Bagg A.

Cancer Genet Cytogenet. 2007 Jan 1;172(1):45-53.

PMID:
17175379
26.

Oligodeoxynucleotide CpG 7909 delivered as intravenous infusion demonstrates immunologic modulation in patients with previously treated non-Hodgkin lymphoma.

Link BK, Ballas ZK, Weisdorf D, Wooldridge JE, Bossler AD, Shannon M, Rasmussen WL, Krieg AM, Weiner GJ.

J Immunother. 2006 Sep-Oct;29(5):558-68.

PMID:
16971811
28.

Exophiala oligosperma causing olecranon bursitis.

Bossler AD, Richter SS, Chavez AJ, Vogelgesang SA, Sutton DA, Grooters AM, Rinaldi MG, de Hoog GS, Pfaller MA.

J Clin Microbiol. 2003 Oct;41(10):4779-82.

Supplemental Content

Loading ...
Support Center